125 related articles for article (PubMed ID: 20979929)
21. Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor linagliptin: a 4-week multicenter, randomized, double-blind, placebo-controlled phase IIa study in Japanese type 2 diabetes patients.
Horie Y; Kanada S; Watada H; Sarashina A; Taniguchi A; Hayashi N; Graefe-Mody EU; Woerle HJ; Dugi KA
Clin Ther; 2011 Jul; 33(7):973-89. PubMed ID: 21723606
[TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetics of capecitabine (Xeloda) in Japanese and Caucasian patients with breast cancer.
Reigner B; Watanabe T; Schüller J; Lucraft H; Sasaki Y; Bridgewater J; Saeki T; McAleer J; Kuranami M; Poole C; Kimura M; Monkhouse J; Yorulmaz C; Weidekamm E; Grange S
Cancer Chemother Pharmacol; 2003 Sep; 52(3):193-201. PubMed ID: 12783206
[TBL] [Abstract][Full Text] [Related]
23. Comparison of the pharmacokinetics of fosfluconazole and fluconazole after single intravenous administration of fosfluconazole in healthy Japanese and Caucasian volunteers.
Sobue S; Tan K; Shaw L; Layton G; Hust R
Eur J Clin Pharmacol; 2004 Jun; 60(4):247-53. PubMed ID: 15103438
[TBL] [Abstract][Full Text] [Related]
24. Efficacy of the specific endothelin a receptor antagonist zibotentan (ZD4054) in colorectal cancer: a preclinical study.
Haque SU; Dashwood MR; Heetun M; Shiwen X; Farooqui N; Ramesh B; Welch H; Savage FJ; Ogunbiyi O; Abraham DJ; Loizidou M
Mol Cancer Ther; 2013 Aug; 12(8):1556-67. PubMed ID: 23723122
[TBL] [Abstract][Full Text] [Related]
25. A phase 1, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and pharmacokinetics of single and multiple doses of lisdexamfetamine dimesylate in Japanese and Caucasian healthy adult subjects.
Ermer J; Martin P; Corcoran M; Matsuo Y
Neuropsychopharmacol Rep; 2020 Mar; 40(1):16-29. PubMed ID: 31765110
[TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetics and Safety of Mavatrep (JNJ-39439335), a TRPV1 Antagonist in Healthy Japanese and Caucasian Men: A Double-Blind, Randomized, Placebo-Controlled, Sequential-Group Phase 1 Study.
Manitpisitkul P; Shalayda K; Russell L; Sanga P; Solanki B; Caruso J; Iwaki Y; Moyer JA
Clin Pharmacol Drug Dev; 2018 Sep; 7(7):712-726. PubMed ID: 29125703
[TBL] [Abstract][Full Text] [Related]
27. Zibotentan for the treatment of castrate-resistant prostate cancer.
Shepard DR; Dreicer R
Expert Opin Investig Drugs; 2010 Jul; 19(7):899-908. PubMed ID: 20497097
[TBL] [Abstract][Full Text] [Related]
28. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Atacicept in a Randomized Trial in Healthy Caucasian and Japanese Subjects.
Willen D; Uhl W; Wolna P; Papasouliotis O; Yalkinoglu Ö
Eur J Drug Metab Pharmacokinet; 2020 Feb; 45(1):27-40. PubMed ID: 31529406
[TBL] [Abstract][Full Text] [Related]
29. Galantamine pharmacokinetics, safety, and tolerability profiles are similar in healthy Caucasian and Japanese subjects.
Zhao Q; Brett M; Van Osselaer N; Huang F; Raoult A; Van Peer A; Verhaeghe T; Hust R
J Clin Pharmacol; 2002 Sep; 42(9):1002-10. PubMed ID: 12211216
[TBL] [Abstract][Full Text] [Related]
30. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
Sarashina A; Sesoko S; Nakashima M; Hayashi N; Taniguchi A; Horie Y; Graefe-Mody EU; Woerle HJ; Dugi KA
Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971
[TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetics of repaglinide in healthy caucasian and Japanese subjects.
Thomsen MS; Chassard D; Evène E; Nielsen KK; Jørgensen M
J Clin Pharmacol; 2003 Jan; 43(1):23-8. PubMed ID: 12520624
[TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetics, Pharmacodynamics, and Safety of Peficitinib (ASP015K) in Healthy Male Caucasian and Japanese Subjects.
Shibata M; Hatta T; Saito M; Toyoshima J; Kaneko Y; Oda K; Nishimura T
Clin Drug Investig; 2020 May; 40(5):469-484. PubMed ID: 32274653
[TBL] [Abstract][Full Text] [Related]
33. The Endothelin-A Receptor Antagonist Zibotentan Induces Damage to the Nasal Olfactory Epithelium Possibly Mediated in Part through Type 2 Innate Lymphoid Cells.
Esvelt MA; Freeman ZT; Pearson AT; Harkema JR; Clines GT; Clines KL; Dyson MC; Hoenerhoff MJ
Toxicol Pathol; 2019 Feb; 47(2):150-164. PubMed ID: 30595110
[TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetics of abiraterone in healthy Japanese men: dose-proportionality and effect of food timing.
Inoue K; Shishido A; Vaccaro N; Jiao J; Stieltjes H; Bernard A; Yu M; Chien C
Cancer Chemother Pharmacol; 2015 Jan; 75(1):49-58. PubMed ID: 25344090
[TBL] [Abstract][Full Text] [Related]
35. Final safety and efficacy analysis of the specific endothelin A receptor antagonist zibotentan (ZD4054) in patients with metastatic castration-resistant prostate cancer and bone metastases who were pain-free or mildly symptomatic for pain: a double-blind, placebo-controlled, randomized Phase II trial.
James ND; Caty A; Payne H; Borre M; Zonnenberg BA; Beuzeboc P; McIntosh S; Morris T; Phung D; Dawson NA
BJU Int; 2010 Oct; 106(7):966-73. PubMed ID: 20840318
[TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetic differences between Caucasian and Japanese subjects after single and multiple doses of a potential combined oral contraceptive (Org 30659 and EE).
de Visser SJ; Uchida N; van Vliet-Daskalopoulou E; Fukazawa I; van Doorn MB; van den Heuvel MW; Machielsen CS; Uchida E; Cohen AF
Contraception; 2003 Sep; 68(3):195-202. PubMed ID: 14561540
[TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetics of mirabegron, a β3-adrenoceptor agonist for treatment of overactive bladder, in healthy Japanese male subjects: results from single- and multiple-dose studies.
Iitsuka H; Tokuno T; Amada Y; Matsushima H; Katashima M; Sawamoto T; Takusagawa S; van Gelderen M; Tanaka T; Miyahara H
Clin Drug Investig; 2014 Jan; 34(1):27-35. PubMed ID: 24178236
[TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetics and tolerability of duloxetine following oral administration to healthy Chinese subjects.
Tianmei S; Knadler MP; Lim MT; Yeo KP; Teng L; Liang S; Pan AX; Lobo ED
Clin Pharmacokinet; 2007; 46(9):767-75. PubMed ID: 17713974
[TBL] [Abstract][Full Text] [Related]
39. Pharmacokinetics and Pharmacodynamics of Ropeginterferon Alfa-2b in Healthy Japanese and Caucasian Subjects After Single Subcutaneous Administration.
Miyachi N; Zagrijtschuk O; Kang L; Yonezu K; Qin A
Clin Drug Investig; 2021 Apr; 41(4):391-404. PubMed ID: 33725322
[TBL] [Abstract][Full Text] [Related]
40. Effects of meal timing relative to dosing on the pharmacokinetics and pharmacodynamics of vildagliptin in Japanese patients with Type 2 diabetes.
He YL; Ito H; Yamaguchi M; Terao S; Shimada S; Irie S; Sekiguchi K
Int J Clin Pharmacol Ther; 2012 Apr; 50(4):237-47. PubMed ID: 22456294
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
